Abstract | The goal of individualized drug therapy requires physicians to be able to accurately predict an individual's response to a drug. Both genetic and environmental factors are known to influence drug response. 'Pharmacogenetics' is the study of the role of inheritance in variation in drug response phenotypes. Pharmacogenetics is now moving genome-wide to become 'pharmacogenomics', resulting in the recognition of novel biomarkers for individual variation in drug response. This article reviews the development, promise and challenges facing pharmacogenomics, using examples of drugs used to treat or prevent cardiovascular disease.
Introduction
Advances in DNA sequencing and genotyping have made it possible to rapidly and accurately identify variation in DNA sequence and structure. As a result, we can now correlate genomic variation with drug response, which helps us to predict individual variation in responses to specific drugs, to optimize drug selection and dose, and to avoid adverse effects associated with drug therapy.
In 1931, Sir Archibald Garrod outlined the basic con cepts underlying genetically programmed individual variation to drugs in his book 'Inborn Factors of Disease' . 1 However, it was not until the 1950s and 1960s that there were data in support of an effect of inheritance on drug response. 2, 3 These data arose from observations indicat ing that individual variation in drug and drug metabo lite concentrations in blood or urine could be related to variation in response to standard drug doses. 2, 3 For example, some patients treated with the muscle relax ant succinylcholine experienced prolonged paralysis and apnea as a result of genetic variation in the activity of butyrylcholinesterase, an enzyme that metabolizes this drug. 4, 5 Subsequently, these adverse reactions were shown to result from an atypical form of the enzyme encoded by a variant allele for the butyrylcholinesterase gene. This allele contained a 209G>A single nucleotide poly morphism (SNP) that altered the encoded amino acid (that is, a nonsynonymous SNP). 6 Researchers now use both genotypetophenotype and phenotypetogenotype strategies to correlate genetic variation with drug response. The genotypeto phenotype approach consists of first determining genetic variation and then evaluating its phenotypic effects, whereas the phenotypetogenotype approach involves beginning with a drugdependent phenotype and then trying to link the phenotype to variation in DNA sequence or structure. The genotypetophenotype approach is now more commonly used because of the availability of DNA sequencing information made possible with the advent of the Human Genome Project.
Traditionally, these studies have been performed by analyzing candidate genes in candidate pathways, selected on the basis of current knowledge-that is, pharmacogenetics (Box 1). The effect of genetic varia tion that results in altered drug response can be classified as being either pharmacokinetic or pharmacodynamic. Pharmacokinetic effects influence the drug's absorption, distribution, metabolism or excretion, thereby influenc ing the concentration of the drug that reaches target. Pharmacodynamic effects influence the drug's target itself and/or signaling pathways downstream from the drug's target.
The advent of genomewide association studies has made it possible to move beyond just performing pharmaco genetic studies and has allowed us to query the effect of DNA sequence variation across the entire genome on drug response-that is, pharmaco genomics. The tradi tional classification of the effects of poly morphisms identi fied by pharmacogenetics can also be applied to genetic effects on drug response that have been identified via pharmacogenomics. Although genomewide associ ation studies can generate many false positive results, usually require large numbers of samples, and are cur rently extremely expensive, 7 they promise to help dramati cally increase our understanding of the contribution of inheritance to variation in drug response.
In this Review, we discuss the development of pharmaco genetics and its evolution into pharmaco genomics using examples of polymorphisms that affect the treatment and/or prevention of cardiovascular disease. The aim of this Review is not to describe all cardio vascular examples known, but to provide exam ples that will facilitate cardiologists' understanding of this important field and the impact it will have on prescribing practices.
Cardiovascular pharmacogenetics
inherited pharmacokinetic effects First described in the early to mid 1970s, a classic example of a pharmacogenetically identified pharmaco kinetic effect is that of inherited variation in the Nacetyltransferase2catalyzed Nacetylation of drugs, such as the vasodilator hydralazine and the anti arrhythmic agent procainamide. 8 'Fast acetylators' had lower plasma concentrations of these drugs and, as a result, were rela tively resistant to therapy, whereas 'slow acetylators' had higher levels and were at risk for drugrelated toxicity like lupus erythematosus. 9, 10 In the late 1970s, genetic variation was described for cytochrome P450, family 2, subfamily D, poly peptide 6 (CYP2D6), which is an important microsomal drug metabolizing enzyme involved in the biotrans formation of many cardiovascular drugs, including the anti arrhythmic agents flecainide and propafenone, and the βblocker metoprolol. 11 Patients who were 'poor meta bolizers' of CYP2D6, 5-10% of the white population, had exaggerated responses to standard doses of CYP2D6 sub strate drugs, such as metoprolol. 12 The CYP2D6 gene was cloned and sequenced in the late 1980s, 13, 14 resulting in the identification of gene deletion and nonsynonymous SNPs associated with being a poor metabolizer, and gene duplication associated with being an 'ultrarapid meta bolizer' . 15 Notably, CYP2D6 gene duplication can vary from a frequency of 1% in europe to 24% in Northern Africa. 16 Indeed, striking ethnic variations in allele types and frequencies have been identified for many poly morphisms of pharmacogenetic importance.
A morerecent example of the discovery of genetic variation resulting in pharmacokinetic effects is a study of polymorphisms in cytochrome P450-in this case cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19)-that affect response to clopidrogel. when treated with clopidogrel, patients with reducedfunction CYP2C19 alleles (30% of the study population) had lower plasma concentration of the active drug metabolite and higher risk for adverse events such as death, myocardial infarction, stroke (a 53% increase in this composite end point) and coronary stent thrombosis (hazard ratio of 3.09) compared with noncarriers, 17 thus identifying a highrisk group that should be targeted with alternative antiplatelet agents.
inherited pharmacodynamic effects The identification of inherited variation in the concentra tion of drug reaching its target (that is, polymorphisms that had pharmacokinetic effects) laid the foundations for the application of pharmacogenetics in the identifi cation of genetic effects on drug targets themselves (that is, of polymorphisms with pharmacodynamic rather than pharmacokinetic effects). Several examples of identified pharmacodynamic effects of polymorphisms involve drugs that are used to treat cardiovascular disease.
Heart failure results in over a million hospitalizations each year in the uS. 18 Despite advances in medical therapy,
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Clinical trials are needed to assess the clinical utility of genotyping in drug ■ therapy and to justify the cost of genetic testing in clinical practice the mortality rate for patients with advanced heart failure approaches 50% at 5 years. 19 The evidence is now clear that inheritance contributes to variation in response to drugs used to treat heart failure. For example, βblockers have been a mainstay in the therapy of systolic heart failure; however, despite many clinical trials showing a distinct reduction in mortality with βblocker therapy, the BetaBlocker evaluation of Survival Trial (BeST) failed to show a significant survival benefit for bucindolol treat ment in patients with class 3-4 heart failure. 20 Response to βblockers is primarily mediated by an effect on the β1adrenergic receptor encoded by ADRB1. At least 13 nonsynonymous SNPs have been described in ADBR1, one of which results in an Arg389Gly mutation, shown to have functional implications that affect outcome after βblocker therapy; this polymorphism alters the intra cellular carboxy terminus of ADRB1, which couples with the stimulatory G protein, G s . 21 The allele encod ing Gly389 has a frequency of 30% in white and Chinese populations and 40% in AfricanAmericans. 22 Individuals homo zygous or hetero zygous for this minor allele exhibit reduced myocardial contractility in response to isoproterenol compared with patients homozygous for Arg389. 23 This observation suggests that ADRB1 with Arg389 might have better coupling efficacy with G s than the Gly389 allozyme. Bucindolol caused a greater decrease in cAmP generation in Arg389 carriers, and patients homo zygous for Arg389 displayed a 38% reduction in mortality (P = 0.03) compared with placebo, whereas Gly389 carriers (hetero zygous or homozygous patients) had a 10% reduction that was not statistically significant (P = 0.57). The improved survival associated with the allele encoding Arg389 was independent of race. 23 Although the Arg389 allele was not shown to be a risk factor for heart failure, black individuals homozygous for Arg389 and for an inherited deletion of four amino acids in the alpha2C adrenergic receptor (ADRA2C), ADRA2C del322-325-which occurs ten times more fre quently in AfricanAmericans than in the white popu lation, and is associated with impaired agonist binding and coupling of the receptor to multiple effector mol ecules 24 -had a tenfold increase in risk for the develop ment of heart failure, compared with a fivefold increase in risk in those only homozygous for the latter variant. 25 This finding illustrates the potential importance of a polygenic approach, that is, taking multiple genes into account in a pharmacogenetic analysis.
This concept was further highlighted by the discovery of a nonsynonymous SNP that generated a Gln41leu polymorphism in the Gproteincoupled receptor kinase GRK5-an enzyme that phosphorylates ADRB1-to result in uncoupling of the receptor from G proteins, thus desensitizing it and simulating pharmacological βblockade. 26 In AfricanAmericans, a population in which this polymorphism is found in approximately 40% of individuals (it is rarely found in white individuals), patients with the leu41 GRK5 allozyme who were not treated with βblockers had a survival benefit similar to those with the Gln41 allozyme who were treated with βblockers. Furthermore, no survival difference was noted between individuals with the leu41 allozyme who were and were not treated with βblockers, which emphasizes the intrinsic βblockadelike effect of this genetic polymorphism and its protective effect against death or time to heart transplantation.
influence of both types of inherited effect Both pharmacokinetic and pharmacodynamic effects should be considered for any one drug that is associ ated with inherited variation in a patients' response to its administration, as some drugs have been shown to be influenced by both types of inherited effects. warfarin is a good example of a drug affected by both inherited pharmacokinetic and pharmacodynamic effects on a patient's response to its administration.
warfarin is widely prescribed as an oral anticoagulant in patients with common cardiac disorders such as atrial fibrillation, and acts by inhibiting the vitamin K cycle required for the posttranslational gamma carboxylation of several blood coagulation factors (Figure 1 ). However, warfarin has a narrow therapeutic index and is one of the most common causes of emergency room visits for adverse drug reactions. 27 The initial loading dose of war farin is empiric, and patients can be either resistant or sensitive to its anticoagulation effect, as monitored by the international normalized ratio (INR).
As early as the 1960s, this variability was suggested to be due, in part, to inherited differences in drug metabolism. 28 warfarin is a racemic mixture, with R and S stereo isomers. Swarfarin is three to five times more potent than the R isomer, and is largely respon sible for the thera peutic effects of the drug. 29 Swarfarin is metabolized by cytochrome P450, family 2, sub family C, polypeptide 9 (CYP2C9), a genetically poly morphic, microsomal drugmetabolizing enzyme with common non synonymous SNPs that result in Arg144Cys (CYP2C9*2) and Ile358leu (CYP2C9*3) alterations in amino acid sequence. Patients heterozygous for the CYP2C9*2 and CYP2C9*3 alleles are at increased risk for hemorrhagic complications during warfarin therapy. 30 However, the SNPs in CYP2C9 account for only 6-18% of the variance in final warfarin dose. Subsequently, after the discovery of vitamin K epoxide reductase complex 1 (vKoRC1), one of the thioldependent enzyme targets of warfarin, 31 VKORC1 haplotypes were found to indepen dently explain 15-30% of the variance in final warfarin dose required. 
REvIEWS
The discovery of VKORC1 haplotypes demonstrates the importance of considering both inherited mutations resulting in pharmacodynamic effects for warfarin and those resulting in pharmacokinetic effects (that is, those that involve CYP2C9), with both having important roles in the identification of patients at risk for the develop ment of INR values greater than four.
33 VKORC1 was not cloned until 2004, 31 which substantially limited our ability to apply pharmacogenetics to warfarin dosing. The combined use of CYP2D9 and VKORC1 genotyping-a 'pathway approach' that uses both pharmacokinetic and pharmacodynamic information-has clearly advanced the clinical utility of warfarin pharmacogenetics.
Genetic testing for CYP2C9*2, CYP2C9*3, and VKORC1 -1639G>A (the major SNP in the haplotype that indicates 'sensitivity') is now available for clinical use. However, it is important to note that clinical co variants such as age, sex, race, height, weight, tobacco use, liver disease and concomitant medication also contribute to the final warfarin dose, and these factors must be included in estimations of appropriate dose. These clini cal factors account for 17-21% of the variability in war farin dosing, while genetic variation alone accounts for 30-35% of the variability. A combination of these factors, as demonstrated in dosing algorithms, could predict up to 55% of warfarin dosing variability without measur ing INR values. 34 In 2009, the International warfarin Pharmacogenetics Consortium published a report showing the utility and success of using a genotypebased approach for predicting warfarin dosing, demonstrating that a pharmacogenetic approach was better in predict ing required warfarin dose than a clinical algorithm alone or a fixed dose approach. 35 The greatest beneficial effect was seen among patients ultimately requiring at least 49 mg per week and those needing 21 mg or less per week, that is 46% of the population treated. As the clinical value of genotypebased dosing for warfarin remains contro versial and has not been examined in a prospective manner on a large scale, the National Heart lung and Blood Institute has initiated a large clinical trial designed to determine the potential value of the addition of genotype data to the determination of INR, particularly during the initiation of warfarin therapy. 36 The example of warfarin pharmacogenetics illus trates the importance of looking for genetic variation that results in pharmacokinetic effects, and that which results in pharmacodynamic effects, when considering any one therapy.
Pharmacogenomics
As demonstrated by warfarin pharmacogenetics, a major limitation of the 'candidate gene' pharmaco genetic strat egy is that it focuses on what we already know, but it is unable to query genes involved in pathways and mech anisms that remain to be discovered. Genomewide associ ation studies potentially provide an opportunity to go beyond our current knowledge by assaying hundreds of thousands of SNP markers across the entire genome.
A good example of where this type of approach has been invaluable is in the treatment of patients using statins. Indeed, one of the first genomewide association studies used to identify genetic variation that might contribute to risk for an adverse drug reaction involved statininduced skeletal myopathy.
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Statins are routinely prescribed to millions of patients for prevention of myocardial infarction and stroke. There is large individual variation in the ability of statins to reduce lDl cholesterol, an important therapeutic end point. Individual variation in genes encoding apo lipoprotein e, cholesterol ester transfer protein and lipo protein lipase do not accurately predict response to statin therapy. 38 Furthermore, known genetic variants of CYP3A4, an enzyme that catalyzes the metabolism of many statins, do not predict risk for the occurrence of adverse response such as myopathy. 39 The Study of the effectiveness of Additional Reductions in Cholesterol and Homocysteine (SeARCH) was a rando mized trial of high dose simvastatin. 37 Patients in the SeARCH trial who developed skeletal myopathy while being treated with 80 mg simvastatin daily, and matched controls, were genotyped using a genome wide associ ation platform that contained approximately 300,000 SNPs scattered across the genome. A strong associ ation with severe myopathy was seen for non coding SNP rs4363657, a polymorphism in intron 11 of the SLCO1B1 gene on chromosome 12 (Figure 2a) . The odds ratio for the development of myopathy was 16.9 among CC homozygotes and 4.5 for CT hetero zygotes as compared with TT homozygotes (Figure 2b) . SLCO1B1 encodes oATP1B1, a solute carrier organic transporter responsible for the active transport of statins into hepato cytes and, thus, plasma clearance and sub sequent metabolism of the drug. Individuals with the C allele had elevated statin blood concentrations, prob ably resulting in a greater risk for myopathy. About 30% of the population in SeARCH was either heterozygous or homozygous for this SLCO1B1 allele, and this SNP could account for approximately 60% of statininduced myo pathy cases in this population. Conceivably, identifica tion of this SNP before starting statin therapy could lead to the recommendation that these patients be prescribed water soluble and hence more 'musclesafe' statins like pravastatin and rosuvastatin. This example is almost certainly only the beginning of a series of genomewide association studies involving drugs that are used to treat cardio vascular disease.
Future directions
Pharmacogenetics and pharmacogenomics represent an important facet of attempts to individualize drug therapy in the present 'genomic' era. The applica tion of genetic information during the clinical thera peutic encounter could potentially decrease costs by directing the most appropriate care to each individual patient rather than a 'blanket approach' based on the average response observed during clinical trials. even REvIEWS though many examples of the successful application of pharmaco genetics now exist, the traditional candidate gene approach has limited us to studies of candidates that we already know. Genomewide association studies may help to address the limitations of that approach. Genomic screens also allow for identification of multiple variants that might incrementally affect response to a particular drug at the same time. what is the foreseeable future of this exciting field?
Potential application problems even after the identification of a functionally important genetic variant, major regulatory, economic and ethical issues will influence the eventual clinical acceptance and application of pharmacogenomic data. There are concerns that coverage and payment decisions by insur ance companies might be affected by such information. The additional value of these tests in clinical care over routine clinical practice will have to be evaluated. By not taking into account individual differences in patients and by promoting effectiveness of therapeutic strategies in groups of patients, comparative effectiveness research supported by the American Reinvestment and Recovery Act might also impede progress in the field.
Although genomewide association studies promise to help make it possible to identify gene variations that predict risk for adverse drug reactions or lack of drug efficacy, acquiring appropriate clinical samples in large numbers, the difficulty of obtaining clearly defined pheno types and the expense of genotyping a large number of samples, currently limits the applica tion of this approach. Furthermore, the low frequency of certain serious adverse drug reactions may also limit its applicability.
Because of the large number of false positives that are generated when hundreds of thousands or millions of SNPs are tested, a standard quality control measure for genomewide association studies is the requirement to replicate findings in an independent population, 7 often a practically difficult and expensive process. In addition, although genomewide association studies can point to unanticipated biological pathways or genes, it is often dif ficult to determine functional mechanisms responsible for the clinical effects of these pathways and/or genes. For that reason, pharmacogenomic model systems that complement clinical genomewide association studies have been developed.
Pharmacogenomic model systems
Clinical genomewide association studies can be complemented by the use of model systems such as celllinebased in vitro systems. one example involves epsteinBarrvirustransformed lymphoblastoid cell lines from hundreds of unrelated individuals of dif ferent ethnic groups, which are available through the NIHsupported Coriell Institute. Panels of these cell lines have been used as one pharmacogenomic model system. Genomewide SNP and expression array data are available for these cell lines, so they can be used to determine drugrelated phenotypes (for example, cytotoxicity) and can then be used to study the role of inheritance in drug response. 40 Specifically, phenotypegenotype analysis can be performed by correlating drug response with genomewide SNPs so novel genes can be identified. Functional studies of SNPs or genes in which the SNPs are found can then be performed in the laboratory and, subsequently, they can be validated by clinical translational studies. A schematic outline of this type of approach is shown diagrammatically in Figure 3 . An example of the successful use of this approach has been demonstrated with two cancer drugs, gemcita bine and cytosine arabinoside. In that case, a variation in the gene for FK506binding protein 5 (FKBP5), a protein not involved in known pharmacokinetic and pharmaco dynamic pathways for these two anti neoplastic cytidine analogs, was found to alter tumor sensitivity to both drugs, in addition to a variation in the gene that encodes cytosolic 5' nucleotidase 3 (NT5C3), a protein that is involved in a known cytidine analog metabo lism pathway. 41 Subsequent studies demon strated that FKBP5 has an important role in response to a variety of anti neoplastic agents. 42 Another example of the use of a celllinebased model system for drug discovery and pharmaco genomics research is the NCI60 cell line collection. This set of REvIEWS cancer cell lines has been extensively profiled at the molecular level more than any other set of cells in exis tence, 43 complementing the Hapmap sample set and the 'Human variation Panel' cell line system.
Clinical translation
A series of important questions must be addressed before the clinical 'translation' of pharmacogenomics. obviously, pharmacogenomic tests must demonstrate clinical utility and their use must help to predict out comes and provide tangible benefit to the patient. This type of diagnostic test must be shown either to be better than existing clinical strategies or to supplement them (for example, geno typing added to the determination of INR for warfarin). The test must also be costeffective and have an appropriate turnaround time in the clinical laboratory. In a valuebased, costconscious environ ment, costeffectiveness will be a major determinant of whether payers will be willing to bear the cost of genetic testing to guide drug therapy. However, by one analy sis, the use of CYP2C9 and VKORC1 genotyping to help determine initial warfarin dose could potentially result in uS$1.1 billion in savings by reducing hemorrhagic compli cations and thromboembolic strokes. 44 obviously, the validity of this type of estimate will have to be deter mined in reallife clinical practice settings. one analysis of costeffectiveness used a markov state transition decision model based on three randomized trials and concluded that genotypeguided warfarin therapy for patients with nonvalvular atrial fibrillation might only be cost effective in a highrisk subgroup during initiation of therapy. 45 what is clear, however, is that the rapid development of genomic technology will accelerate the expansion of our understanding of the role of inheritance in variation in drug response. The large volume of data that will be made available will challenge our ability to integrate this knowledge into clinical practice.
Conclusions
The rapid progress made in genomic medicine, espe cially after completion of the Human Genome Project, has helped us move closer to the goal of individual ized drug therapy. Pharmacogenetics has evolved into pharmacogenomics as we have developed the ability to apply genomewide techniques to study the role of inheritance in drug response phenotypes. These develop ments will eventually make it possible for physicians to moreaccurately predict individual variation in drug response. Implementation of the Genetic Information Nondiscrimination Act of 2008 46 in the uS will help to address patients' concerns with regard to the use of this type of clinical genetic information.
Clinical genotyping of individual genes will almost certainly be a transitory phase in the clinical applica tion of genomics. we have already entered an era when directtoconsumer companies, such as 23andme and Navigenics, offer screening of patients' DNA for over 1 million SNPs at a cost as low as $399, and the day when complete gene sequencing (3 billion nucleotides for under $1,000) will be available for indivi dual patients is possibly as close as 2015. 47 The challenge to physi cians will involve integrat ing this tidal wave of genetic information into the clinical decisionmaking process to better individualize drug therapy. 
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